Viral Vector & Plasmid DNA Manufacturing Market by Cell Line, Type, Transfection, Indication, Workflow, Application, End User

Description

List of Tables

The Global Viral Vector & Plasmid DNA Manufacturing Market is forecasted to grow significantly, with a projected USD 1,506.48 million in 2023 at a CAGR of 25.30% and expected to reach a staggering USD 7,322.62 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Viral Vector & Plasmid DNA Manufacturing Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Viral Vector & Plasmid DNA Manufacturing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Cell Line, market is studied across In-vitro and In-Vivo. The In-vitro commanded largest market share of 88.92% in 2022, followed by In-Vivo.

Based on Type, market is studied across Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA. The Lentivirus commanded largest market share of 34.21% in 2022, followed by Adeno-Associated Virus.

Based on Transfection, market is studied across Stable Transfection and Transient Transfection. The Stable Transfection commanded largest market share of 60.06% in 2022, followed by Transient Transfection.

Based on Indication, market is studied across Cancer, Genetic Disorder, and Infectious Disease. The Cancer commanded largest market share of 38.62% in 2022, followed by Infectious Disease.

Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Fill-finish and Purification. The Upstream Processing is further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting. The Downstream Processing commanded largest market share of 55.34% in 2022, followed by Upstream Processing.

Based on Application, market is studied across Antisense & RNAi, Cell Therapy, Gene Therapy, and Vaccinology. The Cell Therapy commanded largest market share of 34.74% in 2022, followed by Gene Therapy.

Based on End User, market is studied across Biotech Companies and Research Institutes. The Biotech Companies commanded largest market share of 81.22% in 2022, followed by Research Institutes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 40.00% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Viral Vector & Plasmid DNA Manufacturing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Viral Vector & Plasmid DNA Manufacturing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Viral Vector & Plasmid DNA Manufacturing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Viral Vector & Plasmid DNA Manufacturing Market?

4. What is the competitive strategic window for opportunities in the Global Viral Vector & Plasmid DNA Manufacturing Market?

5. What are the technology trends and regulatory frameworks in the Global Viral Vector & Plasmid DNA Manufacturing Market?

6. What is the market share of the leading vendors in the Global Viral Vector & Plasmid DNA Manufacturing Market?

7. What modes and strategic moves are considered suitable for entering the Global Viral Vector & Plasmid DNA Manufacturing Market?

Product Code: MRR-030298DFFC39

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line, 2022 vs 2030
4.3. Viral Vector & Plasmid DNA Manufacturing Market, by Type, 2022 vs 2030
4.4. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection, 2022 vs 2030
4.5. Viral Vector & Plasmid DNA Manufacturing Market, by Indication, 2022 vs 2030
4.6. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow, 2022 vs 2030
4.7. Viral Vector & Plasmid DNA Manufacturing Market, by Application, 2022 vs 2030
4.8. Viral Vector & Plasmid DNA Manufacturing Market, by End User, 2022 vs 2030
4.9. Viral Vector & Plasmid DNA Manufacturing Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising use of viral vectors in several treatments such as cancer demands developments in plasmids and vectors
  - 5.1.1.2. Awareness on the benefits of gene therapy
  - 5.1.1.3. Increase in funding for research and development activities
- 5.1.2. Restraints
  - 5.1.2.1. Limited trained professionals and the complexity of the manufacturing process
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging demand for synthetic genes
  - 5.1.3.2. Approval of gene therapy products from the FDA and other governing bodies
- 5.1.4. Challenges
  - 5.1.4.1. Ethical concern, logistical issues, and associated cost
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line

6.1. Introduction
6.2. In-vitro
6.3. In-Vivo

7. Viral Vector & Plasmid DNA Manufacturing Market, by Type

7.1. Introduction
7.2. Adeno-Associated Virus
7.3. Adenovirus
7.4. Lentivirus
7.5. Plasmid DNA

8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection

8.1. Introduction
8.2. Stable Transfection
8.3. Transient Transfection

9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication

9.1. Introduction
9.2. Cancer
9.3. Genetic Disorder
9.4. Infectious Disease

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow

10.1. Introduction
10.2. Downstream Processing
- 10.2.1. Fill-finish
- 10.2.2. Purification
10.3. Upstream Processing
- 10.3.1. Vector Amplification & Expansion
- 10.3.2. Vector Recovery/Harvesting

11. Viral Vector & Plasmid DNA Manufacturing Market, by Application

11.1. Introduction
11.2. Antisense & RNAi
11.3. Cell Therapy
11.4. Gene Therapy
11.5. Vaccinology

12. Viral Vector & Plasmid DNA Manufacturing Market, by End User

12.1. Introduction
12.2. Biotech Companies
12.3. Research Institutes

13. Americas Viral Vector & Plasmid DNA Manufacturing Market

13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market

14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market

15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape

16.1. FPNV Positioning Matrix
16.2. Market Share Analysis, By Key Player
16.3. Competitive Scenario Analysis, By Key Player

17. List of Company Mentioned

18. Appendix

18.1. Discussion Guide
18.2. License & Pricing